CN Patent

CN112028896A — 阿卡替尼的新晶型及其制备方法

Assigned to Aoruite Pharmaceutical Tianjin Co ltd · Expires 2020-12-04 · 5y expired

What this patent protects

本发明属于化合物合成技术领域，具体说是阿卡替尼的新晶型及其制备方法，阿卡替尼的四种阿卡替尼的新晶型，均经过PXRD、DSC、HNMR、IR、TGA检测确认，APTI‑I、APTI‑II（阿卡替尼与麦芽醇的共晶物）、APTI‑III（阿卡替尼与乙基麦芽酚的共晶物）、APTI‑IV（阿卡替尼与丁二酸的共晶物）的制备操作简单，成本低，易于放大生产，为制剂研发提供新的选择。

USPTO Abstract

本发明属于化合物合成技术领域，具体说是阿卡替尼的新晶型及其制备方法，阿卡替尼的四种阿卡替尼的新晶型，均经过PXRD、DSC、HNMR、IR、TGA检测确认，APTI‑I、APTI‑II（阿卡替尼与麦芽醇的共晶物）、APTI‑III（阿卡替尼与乙基麦芽酚的共晶物）、APTI‑IV（阿卡替尼与丁二酸的共晶物）的制备操作简单，成本低，易于放大生产，为制剂研发提供新的选择。

Drugs covered by this patent

Patent Metadata

Patent number
CN112028896A
Jurisdiction
CN
Classification
—
Expires
2020-12-04
Drug substance claim
No
Drug product claim
No
Assignee
Aoruite Pharmaceutical Tianjin Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.